Frank DeRosa serves as Chief Technology Officer at Translate Bio and joined the team in 2016. Prior to joining Translate Bio, Frank was Senior Director of Preclinical Research and Process Development for the mRNA therapeutics platform at Shire. He also worked at Enzon Pharmaceuticals developing polymer and lipid nanoparticle-based delivery systems for locked nucleic acid (LNA) antisense technology. Frank has previously held roles at Takasago International Corporation and the National Cancer Institute (NIH) focused on small molecule library synthesis and polymer-drug conjugate analogues, respectively. He is a co-inventor on over 50 issued patents and more than 75 additional pending patent applications. In addition, he is a co-author on eighteen scientific publications. Frank received his Ph.D. from the University of California, Santa Barbara.